

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4

In re Patent Application of

BROWN et al

Atty. Ref.: 4450-12

Serial No. Unassigned

TC/A.U.: Unassigned

Filed: March 17, 2005

Examiner: Unassigned

For: DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR
USE IN CANCER THERAPY

* * * * *

March 17, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


Attached is a completed Form PTO-1449 listing references in connection with this application. Also enclosed is a copy of each of those references, along with the International Search Report.

The Examiner is requested to initial the attached PTO-1449, and to return a copy of the initialed document to the undersigned as an indication that the listed references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

4450-12

S. L. NO.

Unassigned

10/528156 #4

APPLICANT

BROWN et al

(Use several sheets if necessary)

FILING DATE

March 17, 2005

TC/A.U.

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,827,850	10/1998	Brown et al			
	DD 272,591	10/1989	Niclas et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 91/04028	04/1991	WO			
EP 0 972 571 B1	01/2000	EP			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Delahoussaye et al; "Improved potency of the hypoxid cytotoxin tirapazamine by DNA-targeting"; pp 1807-1815; <i>Biochemical Pharmacology</i> ; Vol. 65 (11) (2003).
	Parrick et al; "The Synthesis of a Potential Anti-Cancer Agent Containing he Caffine and 1,2,4-Benzotriazine Moieties"; pp 323-327; <i>Journal of Heterocyclic Chemistry</i> ; Vol. 30(2) (1993).
	Mehta et al; "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP"; pp 227-241; <i>Anti-Cancer Drug Design</i> ; Vol. 10(3) (1995).
	Hay, et al; "Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine"; <i>Journal of Medicinal Chemistry</i> ; Vol. 46(1), pp. 169-182 (2003).
	Kelson et al; "1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumour activity"; <i>Chemical Abstracts</i> , Vol. 129; pp. 575-592; Abstract 339530 (& <i>Anti-Cancer Drug Design</i> , Vol. 13(6) (1998).
	Minchinton et al; "Second generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive antitumour agents: pharmacology and activity in vitro and in vivo"; pp. 701-705; <i>Chemical Abstracts</i> ; Vol. 116, Abstract 187502 (& <i>Int'l Journal of Radiation Oncology, Biology, Physics</i> , Vol. 22(4) (1992).
	Argyropoulos et al; "Cycloadditions of nitril oxides with benzofuran n-oxides"; pp 3277-3287; <i>Chemical Abstracts</i> ; Vol. 114; Abstract 164101 (& <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> , Vol. 12 (1990).
	Tocher et al; "Electrochemical studies and DNA damaging effects of the benzotriazine-N-oxides"; pp 781-786; <i>Chemical Abstracts</i> , Vol. 112; Abstract 171760 (& <i>Biochemical Pharmacology</i> , Vol. 39(4) (1990).
	Zeman et al; "Structure-activity relationships for benzotriazine di-N-oxides"; pp 977-981; <i>Chemical Abstracts</i> ; Vol. 111; Abstract 3393 (& <i>International Journal of Radiation Oncology, Biology, Physics</i> , Vol. 16 (4) (1989).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.